ESSA PHARMA INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.12 USD | -1.92% |
|
+3.17% | -6.21% |
| May. 20 | Top Premarket Decliners | MT |
| Mar. 06 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call |
Presenter SpeechMark Breidenbach (Analysts)All right. Thanks for joining us on Day 3 of Oppenh...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Calendar
2024-08-12
- Q3 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.492
CAD
Average target price
26.69
CAD
Spread / Average Target
+214.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.21% | 276M | |
| +44.31% | 54.04B | |
| +43.57% | 41.96B | |
| -1.25% | 41.92B | |
| -7.59% | 28.35B | |
| +12.19% | 26.35B | |
| -21.99% | 19B | |
| +7.26% | 13B | |
| +29.40% | 12.28B | |
| +25.21% | 12.19B |
- Stock Market
- Equities
- EPIX Stock
- News ESSA Pharma Inc.
- Transcript : ESSA Pharma Inc. Presents at Oppenheimer 31st Annual Healthcare Conference, Mar-18-2021 11